Yahoo · Sep 29, 2026
Carlsmed names new CFO
Former ZimVie CFO Richard Heppenstall fills the vacancy created by the departure of Leo Greenstein, who is leaving Carlsmed to pursue other professional interests.
CA
NASDAQ · CARL
CARLSMED, INC.
Healthcare · Medical - Healthcare Information Services
$14.07
Down-$0.29 (-2.06%)
Updated Oct 1, 2026, 7:40 PM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 348.63M
- P/E ratio
- -10.74
- Dividend yield
- 0.00%
- 52-week range
- $8.50 – $17.23
- Volume
- 56.8K
- Avg. volume
- 96.69K
Price performance · CARL
CARL price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Sep 30, 2026
CARL closed at $14.07 after 20 trading sessions, down 13.89% for the selected period.
- Last close
- $14.07
- Period change
- -13.89%
- Period low
- $14.07
- Period high
- $16.34
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 30, 2026 | $13.99 | $14.13 | $13.56 | $14.07 | 56.8K |
| Sep 29, 2026 | $14.14 | $14.2064 | $13.63 | $14.09 | 53.83K |
| Sep 28, 2026 | $14.88 | $14.88 | $14.10 | $14.18 | 52.94K |
| Sep 25, 2026 | $14.79 | $15.35 | $14.69 | $15.10 | 65.42K |
| Sep 24, 2026 | $14.70 | $14.93 | $14.43 | $14.82 | 45.21K |
| Sep 23, 2026 | $15.33 | $15.6899 | $14.55 | $14.76 | 61.83K |
| Sep 22, 2026 | $15.62 | $15.85 | $15.2801 | $15.42 | 61.31K |
| Sep 21, 2026 | $15.67 | $15.78 | $15.1701 | $15.60 | 58.98K |
| Sep 18, 2026 | $15.38 | $15.88 | $15.13 | $15.58 | 238.37K |
| Sep 17, 2026 | $15.57 | $15.64 | $15.13 | $15.39 | 73.87K |
| Sep 16, 2026 | $15.26 | $15.615 | $15.11 | $15.31 | 55.06K |
| Sep 15, 2026 | $15.20 | $15.55 | $14.75 | $15.23 | 93.73K |
| Sep 14, 2026 | $14.89 | $15.475 | $14.89 | $15.34 | 63.17K |
| Sep 11, 2026 | $14.98 | $15.44 | $14.72 | $14.73 | 98.88K |
| Sep 10, 2026 | $14.88 | $15.29 | $14.74 | $14.76 | 59.16K |
| Sep 9, 2026 | $15.19 | $15.86 | $14.93 | $14.99 | 53.39K |
| Sep 8, 2026 | $15.37 | $15.37 | $15.01 | $15.23 | 63.86K |
| Sep 4, 2026 | $15.38 | $15.88 | $15.38 | $15.60 | 46.73K |
| Sep 3, 2026 | $16.48 | $16.65 | $15.4491 | $15.52 | 158.81K |
| Sep 2, 2026 | $16.44 | $17.20 | $16.25 | $16.34 | 116.02K |
Latest CARL news
The latest Smart Investors Daily articles mentioning CARL.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CARL research
Overview
Company profile and research snapshot.
Company profile
Carlsmed Inc is a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. It is focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of AI-enabled software solutions, and interbody implants that it custom design for each patient's unique pathology and vertebral bone topography, and single-use surgical instruments. The Company designs, manufactures, and markets aprevo, a comprehensive technology platform for spine fusion surgery procedures.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $18.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 28, 2026 | BTIG | Buy | — |
| Aug 6, 2026 | Truist Securities | Buy | — |
| Jul 1, 2026 | Needham | Buy | — |
| May 6, 2026 | BTIG | Buy | — |
| Apr 15, 2026 | Truist Securities | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 28, 2026
Carlsmed Appoints Richard Heppenstall as Chief Financial Officer
Company Reaffirms Fiscal Year 2026 GuidanceCARLSBAD, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Richard Heppenstall has been appointed Chief Financial Officer, effective immediately. Mr. Heppenstall succeeds Leo Greenstein, who has served as CFO since 2023 and will be leaving Carlsmed to pursue other professional interests. “We
Benzinga · Sep 28, 2026
BTIG Reiterates Buy on Carlsmed, Maintains $23 Price Target
BTIG analyst Ryan Zimmerman reiterates Carlsmed (NASDAQ:CARL) with a Buy and maintains $23 price target.
Benzinga · Sep 28, 2026
Carlsmed Affirms FY2026 Sales Guidance of $74.000M-$78.000M vs $74.830M Est
Carlsmed (NASDAQ:CARL) affirms FY2026 sales outlook from $74.000 million-$78.000 million to $74.000 million-$78.000 million vs $74.830 million estimate.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
